H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

November 19, 2024 6:55 AM EST Send to a Friend
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $50.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login